Epithalon

What Epithalon is

Epithalon is a lab-made peptide that has been tested in about 30 to 40 studies. Most used rats, mice, fruit flies or human cells in a dish. One study followed older patients for years. It was not randomized, and it used epithalamin, the cattle extract, not Epithalon itself. As of April 2026, no major Western regulator has approved it, including the FDA, the EMA and the MHRA. It is sold only as a research peptide.

A peptide is a short chain of amino acids, the building blocks of protein. Epithalon, also written epitalon, has just four: Ala-Glu-Asp-Gly, or AEDG. It weighs about 390 Da. Few active peptides in aging research are smaller.

It was built as a lab-made stand-in for epithalamin. Epithalamin is a mix of peptides taken from the pineal gland of cattle. The pineal is a small gland in the brain.

Professor Vladimir Khavinson first described Epithalon. He worked in Russia, at the Institute of Bioregulation and Gerontology in Saint Petersburg. His research program has run for more than 30 years. It grew out of an idea he calls “peptide bioregulation”. The idea is that short peptides can act on specific stretches of genes. That would control which proteins get made and bring back function lost with age. Nearly all the published data on Epithalon come from his one group.

Scientists study Epithalon for three things:

• Telomerase. This is the main interest. Telomeres are the caps on the ends of chromosomes. Telomerase is the enzyme that keeps them long. Shorter telomeres are a well-known mark of aging cells. So compounds that act on telomerase get a lot of notice in aging science. Epithalon is reported to switch it on.
• The pineal gland and melatonin. This follows from its origin as a copy of a pineal extract.
• Antioxidant effects. Newer studies added these to the list.

How much research there is

There are a few dozen studies, nearly all from one lab in Saint Petersburg, and almost no human data.

Question	Answer
Peer-reviewed studies	About 30 to 40. This guide cites 11 key ones
What was tested	Mostly live rats, mice and Drosophila fruit flies, plus human cell lines in a dish
People studied	One long observational study, and it used the parent extract epithalamin, not Epithalon. It was not randomized
Checked by other labs	Very little. A 2025 study in Biogerontology is among the few from outside the group
Where the work comes from	More than 90% of published studies come from one group, Khavinson and Anisimov in Saint Petersburg
How the body handles it	Nothing published for humans. A small amount of animal data
Randomized controlled trials	None in indexed journals
Agreement on dose	None. No dosing plan rests on evidence, and what circulates is anecdote
Long-term safety	Animal lifespan studies point to no harm. There are no formal safety studies in humans

How it might work

The reported effects fall into three linked pathways. Almost all of this comes from cells in a dish and from animals. Few Western labs have confirmed any of it, and the exact steps at the level of molecules are not settled.

Telomerase

Telomerase is the mechanism cited most often. The part that matters is hTERT, short for human telomerase reverse transcriptase. It is the working core of the enzyme.

Most adult human body cells keep the hTERT gene switched off by chemical tags on the DNA. Without telomerase, telomeres get shorter each time a cell divides. In the end the cell stops dividing, a state called senescence, or it dies by apoptosis. This is at the heart of how cells age.

The proposal is that Epithalon acts on specific DNA sequences and lifts the block on hTERT. Lab studies report that human body cells with no telomerase began to make it after Epithalon. Their telomeres grew longer, and the cells could divide more times [1].

A 2025 paper in Biogerontology put numbers on this in several human cell lines. Telomeres grew more as the dose went up. hTERT mRNA, the working copy of the gene, rose by a measurable amount, and so did telomerase enzyme activity [7]. The same paper found something else. Some cell lines grew longer telomeres without telomerase. They used a second route called alternative lengthening of telomeres, or ALT. So the story may be more tangled than first proposed.

Telomerase cuts both ways. It might slow senescence or even reverse it. But telomerase that runs unchecked is a hallmark of about 85 to 90% of human cancers. No long-term study has dealt properly with whether Epithalon’s effect on telomerase carries a cancer risk.

The pineal gland and melatonin

Because Epithalon is modeled on a pineal extract, scientists have tested what it does to that gland and to melatonin.

In rat pinealocytes, the cells of the pineal gland, Epithalon raised two things [8]:

• AANAT (arylalkylamine N-acetyltransferase), the enzyme that sets the pace of melatonin production
• phospho-CREB, the active form of cAMP response element-binding protein

This suggests it pushes the enzymes of the melatonin pathway directly. That may help restore the daily body clock in aging animals. Most mammals make less melatonin as they age. The drop is linked to poor sleep, weaker antioxidant defenses and a weaker immune system.

A second clue comes from the fruit fly, Drosophila melanogaster. That study used epithalamin, the parent extract, not Epithalon. The extract lengthened the life of female flies and cut free radical damage in their tissues [5].

This pathway could also tie Epithalon to wider effects in the body. Melatonin is more than a sleep hormone. It is a strong antioxidant, it tunes the immune system, and it sets body rhythms. If Epithalon truly restores melatonin lost with age, the knock-on effects could reach many body systems at once.

Antioxidant defenses

In aging rodents, Epithalon is reported to make some key antioxidant enzymes more active [6]:

• superoxide dismutase (SOD)
• glutathione peroxidase (GPx)
• glutathione-S-transferase (GST)

The proposed route is Nrf2. The name stands for nuclear factor erythroid 2-related factor 2. Nrf2 is a master switch for the antioxidant defenses of a cell.

Melatonin is itself a strong mop for free radicals. So the antioxidant effect could be direct, or it could come by way of more melatonin, or both. Nobody has settled whether the two effects depend on each other, stand apart, or add up.

A 2025 paper used a lab dish model of diabetic retinopathy, which is eye damage from diabetes. It ran in the journal Stem Cell Reviews and Reports. Epithalon helped wounds heal in the model, and the authors credited its antioxidant activity [9]. This is one of the newer branches of the research. Earlier work stayed with telomerase and the pineal gland.

What the studies found

All of the studies cited here were peer reviewed. Most used animals or cells in a dish. The human data are observational and limited in method.

Telomeres

This is the most distinctive part of the Epithalon record.

• Telomerase switched on. Khavinson and colleagues (2003) worked with cultures of human fetal fibroblasts, a kind of connective tissue cell. The cells had no telomerase before. After Epithalon they showed telomerase activity and longer telomeres. No earlier paper had shown a short lab-made peptide turning telomerase back on in normal cells from humans [1].
• More with higher doses. The 2025 Biogerontology study confirmed that telomeres grew longer as the dose rose in several human cell lines. It gave figures for hTERT mRNA. It also found the ALT route in some cell lines, so the effect on telomeres may not rest on telomerase alone [7].

Lifespan

Lifespan studies are a large share of the evidence. All of them used animals or insects.

• Rats and mice. Anisimov, Khavinson and Morozov (1994) covered two decades of long-term animal studies of epithalamin, the parent compound of Epithalon. They reported that it raised both average and maximum lifespan in rats and mice [2].
• SHR mice. One study gave Epithalon to female Swiss-derived SHR mice starting at 3 months of age. Average lifespan went up, and fewer tumors appeared spontaneously [3]. The tumor result stands out, given the worry about telomerase and cancer.
• Fruit flies. Epithalamin, not Epithalon, lengthened life in female Drosophila melanogaster. The effect was put down to less free radical oxidation [5].

Every lifespan study comes from one research group, that of Anisimov and Khavinson in Saint Petersburg. For Epithalon, no independent lab has put out lifespan data in any species.

Melatonin and the body clock

The Khavinson and Anisimov group has published on melatonin for several decades.

• Pineal cells. Epithalon raised both AANAT and pCREB in rat pinealocytes. That points to a direct push on the enzymes that make melatonin, not a roundabout hormone effect [8].
• Aging animals. In aging rodents whose natural melatonin output had dropped, epithalamin was reported to raise production. In effect the gland was “reset” to a younger working state.
• Immune measures. Immune readings improved as melatonin came back. That fits the known role of melatonin in tuning the immune system [6].

Antioxidants and wound healing

• Enzymes. SOD, GPx and GST activity rose in aging rats, and the Nrf2 pathway was proposed as the cause [6].
• Diabetic retinopathy. The 2025 lab dish study showed better wound healing in its retinopathy model and credited the antioxidant effect. It is a new direction. It ties the peptide to metabolic disease for the first time [9].

People

Human data are very scarce, and weak by modern standards.

In 2003, Khavinson and Morozov reported on 266 older people who were followed for 6 to 8 years. Some received epithalamin, the pineal extract. Some received thymalin, a thymus extract. Some received both. Fewer of them died than in the control group [4]. The study did not use Epithalon, the lab-made peptide.

The caveats are large:

• The design was observational, not randomized.
• It tested epithalamin, the cattle extract, not Epithalon.
• Some patients also got thymalin, so it is unclear which one did what.
• The authors belong to the same group that made both compounds.
• No one has repeated it independently.

No indexed Western journal has published a large, double-blind, placebo-controlled randomized trial of Epithalon.

The retina

Reviews by the Khavinson group cite a result in retinitis pigmentosa, an inherited eye disease. They say that 90% of treated patients had a positive clinical effect [8].

Indexed journals do not offer the full trial design, the sample size, the main endpoints or the statistics. Until the complete methods and data are published, the finding is preliminary and unverified.

Where the research comes from

Epithalon cannot be judged apart from the program that produced it. Khavinson started the work on Epithalon and is its lead scientist. He also started the wider field of “peptide bioregulation.”

His record is large. He has more than 775 scientific publications. He also holds 196 patents, Russian and international. His major works include a 2002 paper in Neuroendocrinology Letters and a 2005 book from Karger AG [10], [11].

His group produced the bulk of the data on Epithalon. That includes the studies of telomerase, lifespan and melatonin, and the observational study in humans. Professor Vladimir Anisimov, his partner of many years, co-wrote the research on lifespan and tumor rates.

Having so much evidence in one program does not rule the findings out. It does make independent checks matter more. In mature fields, several separate groups usually confirm a key finding before scientists accept it widely. For Epithalon, that mostly has not happened yet.

In 2025 a broad review looked back over 25 years of work on Epithalon. It ran in the International Journal of Molecular Sciences. It covered telomerase, antioxidant effects, protection of nerve cells and protection against mutations [8]. The review was thorough. It also stressed two things that are still needed: replication by independent labs, and evidence of clinical grade.

Safety

In animals

• Treated rodents in lifespan studies did not get more tumors. SHR mice had fewer spontaneous tumors [3].
• No published animal or cell study reports sudden poisoning, organ damage or death.
• Animals seemed to tolerate the tested doses well over long treatment periods.

Telomerase and cancer

The biggest safety worry is a theory, and it comes from the main proposed mechanism. About 85 to 90% of human cancers show active telomerase. Tumor cells turn it back on so they can divide without limit. So a compound that turns it on in normal cells raises a question. Could it start cancer or speed it up?

The animal evidence so far is somewhat reassuring. Tumors went down, not up, in the SHR mouse study [3]. But that is one study in one strain of mouse. It cannot rule out a cancer risk in humans, least of all with long-term use. With no long-term human safety data, the question is still open.

What is not known

• There is no full human safety record at any dose or for any length of time.
• Drug interactions have not been formally studied.
• Nobody knows the long-term result of turning on telomerase again and again in human tissue.
• Effects on cells that are already cancerous, or close to it, have not been studied well enough.
• There is no safety data by sex, on reproduction or on development.
• Batches can differ. There is no standard way of making it and no pharmacopoeia monograph, the official quality standard for a drug.
• Quality control of products on the market is not regulated or standardized.

Legal status in the US

• Not FDA approved. Epithalon has no approval for medical use from the FDA. The EMA, the MHRA and the other major Western regulators have not approved it either.
• Not a registered drug in Russia either. It began in Russian research. Scientists there have studied it as a bioregulatory peptide. It does not hold standard drug approval there.
• Sport. The World Anti-Doping Agency Prohibited List has a class called S0, for non-approved substances. Peptides not approved for medical use in humans may fall under it.
• Research use and quality. It is an unregulated research peptide. No regulator guarantees that a product is pure, sterile, or what the label says.

Limits of the research

1. One source. This is the biggest limit. Nearly all of the research comes from the Khavinson and Anisimov group in Saint Petersburg. Unconnected Western labs have largely not repeated it. That sets Epithalon apart from compounds with a wider research base. It goes to the core of how much trust the science can earn.
2. No randomized controlled trials. No large, placebo-controlled, double-blind trial has appeared in a major Western journal. The human data that exist are observational and limited in method by modern standards.
3. Hard-to-reach papers. Some key findings sit in Russian-language journals, or in publications that PubMed and Scopus do not index widely. That makes them hard to verify and review.
4. Telomerase cuts both ways. It may slow the aging of cells. But unchecked telomerase is a cancer hallmark. No safety study has run long enough to test properly whether ongoing use carries a cancer risk for people.
5. Mechanism not confirmed. The effects might run through telomerase, through melatonin, through antioxidant pathways, or through a mix. Nobody has shown which. The ALT finding in the 2025 Biogerontology study clouds the picture more [7].
6. No agreed dose. There is no consensus on the best dose, the route, the length of a cycle or long-term plans. Most dosing talk online is anecdote, not evidence.
7. Mixed-up human data. The one long observational study in humans used epithalamin, the cattle extract, not Epithalon. Some patients also got thymalin. The effects cannot be pinned on Epithalon [4].
8. Missing negative results. Almost all the studies come from one group and report positive results. Studies that found nothing may never have been submitted or published, and that cannot be ruled out.

One lab has spent decades reporting that Epithalon lengthens telomeres and extends life in cells and animals. Almost no one else has checked, and no proper human trial exists.

References

Selected peer-reviewed references. Ordered by relevance to this guide.

1. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590–592. DOI: 10.1023/A:1025493705728
2. Anisimov VN, Khavinson VKh, Morozov VG. Twenty years of study on effects of pineal peptide preparation: epithalamin in experimental gerontology and oncology. Annals of the New York Academy of Sciences. 1994;719:483–493. PMID: 8010617. DOI: 10.1111/j.1749-6632.1994.tb56853.x
3. Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193–202. DOI: 10.1023/A:1025114230714
4. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuroendocrinology Letters. 2003;24(3/4):233–240. PMID: 14523363
5. Anisimov VN, Mylnikov SV, Oparina TI, Khavinson VKh. Effect of melatonin and pineal peptide preparation epithalamin on life span and free radical oxidation in Drosophila melanogaster. Mechanisms of Ageing and Development. 1997;97(2):81–91. PMID: 9226628. DOI: 10.1016/S0047-6374(97)01897-6
6. Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139–149. DOI: 10.1007/s10522-009-9249-8
7. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. DOI: 10.1007/s10522-025-10315-x
8. Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences. 2025. PMC: PMC11943447
9. The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy. Stem Cell Reviews and Reports. 2025. DOI: 10.1007/s12015-025-10911-x
10. Khavinson VKh. Peptides and Ageing. Neuro Endocrinology Letters. 2002;23(Suppl 3):11–144. PMID: 12374906
11. Khavinson VKh. Gerontological Aspects of Genome Peptide Regulation. Basel: Karger AG; 2005.